Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies.
Twelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25% mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lymph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50% of three tumors, 50% and 75% of six, and more than 75% of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.
Ro
J Y
JY
Department of Pathology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Grignon
D J
DJ
Ayala
A G
AG
Fernandez
P L
PL
Ordonez
N G
NG
Wishnow
K I
KI
D000135:Acid Phosphatase / Q000097:blood / Q000378:metabolism; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000378:metabolism; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D006651:Histocytochemistry; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*
D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D009077:Mucins; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen